CADASIL
MeSH: D046589ORPHA: 1361 Treatment Available
Overview
autosomal dominant cerebrovascular disorder characterized by recurrent subcortical ischemic stroke and cognitive impairment
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Cerebrolysin | Injection | Available in some countries | 4 | — |
Clinical Presentation
Signs and symptoms associated with CADASIL, sourced from HPO and Orphanet clinical annotations.
LeukoencephalopathyAbnormal cerebral white matter morphologyLacunar strokeMultifocal hyperintensity of cerebral white matter on MRIEmotional labilityApathyStrokeMigraineMigraine with auraTransient ischemic attackCerebral ischemiaCognitive impairmentDepressionDementiaAnxietyDiabetes mellitusHypertensionSeizureSpasticityDysarthriaGait disturbanceConfusionEncephalopathyParkinsonismCerebral hemorrhageDysphagiaIschemic strokeIntracranial hemorrhageHemiplegiaMotor deteriorationMemory impairmentLanguage impairmentLoss of consciousnessRecurrent subcortical infarctsImpaired visuospatial constructive cognitionStress urinary incontinenceBrain atrophyAbnormally slow thought processArterial stenosisAphasia
Classification & Codes
MeSH Code
D046589Orphanet Code
ORPHA:136CADASIL
| MeSH | D046589 |
| Orphanet | ORPHA:136 |
| Treatments | 1 drug(s) |
| Symptoms on record | 40 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO